Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is demonstrating strong progress across its various programs, as evidenced by numerous upcoming milestones and catalysts, commendable preliminary data from its NBTXR3 and Nanoray platforms in multiple indications, and continued enrollment in its ISTs. With a sizable TAM estimated at $12-14B in just its three initial indications of focus, the company has significant potential for growth and upside. Additionally, its strong partnership with JNJ and positive updates from its lead program NBTXR3 give confidence in its future success.

Bears say

Nanobiotix is heavily reliant on the success of its nanotechnology-based product candidate, NBTXR3, which is still in clinical trials and faces potential risks and delays. Additionally, the company's valuation is heavily based on its potential success in the treatment of cancer, which is a highly competitive and complex market. The recent operational progress and ongoing partnerships do provide some upside potential, but overall, the success of the company's product candidate remains uncertain.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.